Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7978037 | 0.82 | BTK (0.30) | LMNA | |
| SCHEMBL8880684 | 0.79 | RBP4 (0.33) | — | |
| Ammonia Solution, Strong SCHEMBL28588874 | 0.77 | RBP4 (0.33) | — | |
| SCHEMBL4742520 | 0.76 | CYP4F2 (0.31) | — | |
| SCHEMBL4829842 | 0.76 | NPSR1 (0.31) | — | |
| SCHEMBL8019790 | 0.75 | PLG (0.31) | PLGPLATLMNA | |
| SCHEMBL23293553 | 0.74 | CYP2C19 (0.32) | — | |
| SCHEMBL8928112 | 0.74 | PLG (0.45) | PLGPLATLMNACYP2D6 | |
| SCHEMBL8145030 | 0.74 | DGAT1 (0.35) | — | |
| SCHEMBL7884001 | 0.73 | CYP2C19 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-20240307359-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORP (US) | 2024-09-19 | — | — | US | disclosed |
| US-11931347-B2 | Method of screening for agents for differentiating stem cells | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| CN-113527289-A | Method for screening agent for differentiating stem cells | 米纳瓦生物技术公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| CN-110799652-A | Differentiated stem cells and agents for treating cancer | 米纳瓦生物技术公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20180263964-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2018-09-20 | — | — | US | disclosed |
| WO-2001054507-A1 | METHODS FOR KILLING NEMATODES AND NEMATODE EGGS USING OXADIAZOLE AND OXAIMIDAZOLE COMPOUNDS | AKKADIX CORPORATION (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001002375-A1 | PROCESS FOR SYNTHESIZING OXADIAZOLES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| EP-0763016-B1 | COMPOSITIONS AND METHODS FOR TREATING MAST-CELL MEDIATED CONDITIONS | AXYS PHARM INC (US) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263964-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MCL1, CRABP2, MYADM | PLG 2278/4885PLAT 2863/4885LMNA 3544/4885 |
| US-11931347-B2 | Method of screening for agents for differentiating stem cells | MCL1, CRABP2, MYADM | PLG 2278/4885PLAT 2863/4885LMNA 3544/4885 |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | PLG 2238/4885PLAT 2078/4885LMNA 3425/4885 |
| US-20240307359-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MCL1, CRABP2, MYADM | PLG 2278/4885PLAT 2863/4885LMNA 3544/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | PLG 1893/4885PLAT 2292/4885LMNA 3414/4885 |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | PLG 1893/4885PLAT 2292/4885LMNA 3414/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | PLG 4638/4885PLAT 4608/4885LMNA 1385/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | PLG 1893/4885PLAT 2292/4885LMNA 3414/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | PLG 1893/4885PLAT 2292/4885LMNA 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.